San Diego – January 12, 2017 – Cooley advised Mirati Therapeutics on its $68.7 million shelf-takedown offering of 5,002,702 shares of common stock and pre-funded warrants to purchase 7,258,263 shares of common stock, which included the full exercise of the underwriter’s option to purchase additional shares.
Mirati, which trades on the NASDAQ Capital Market under “MRTX,” is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.